This research focuses on the development of controlled-release tablets containing 200 mg of Dolutegravir sodium, a second-generation antiretroviral drug used in HIV treatment. Six formulations were designed using the direct compression method, incorporating varying concentrations of hydrophobic polymers along with different excipients as fillers. The prepared formulations were subjected to pre-compression and post-compression evaluations, along with in-vitro dissolution studies. Based on dissolution profiles, formulation F6 was identified as the optimized formulation, as it exhibited superior controlled drug release and aligned best with the desired kinetic model. Keywords: Dolutegravir (DTG), HPMC K15M, Carbopol 971G, Microcrystalline Cellulose (MCC), Controlled Release Tablets.